us quarter on Thanks, Karina. fourth Good earnings and afternoon, our everybody, joining full for year you and thank XXXX call.
the as selection call. discuss upcoming candidate, many progress continue our we year achievements in all during to changing challenging cancer of workplace. potential start Adaptive, in their for TCR of Genentech's flexibility with execution are dedication, to the therapeutic off adjust another of later base a neoantigen want which for which for Indeed, targeting to was the thank we and as I candidate of set I'll key our to dynamics a shared product a great a solid always, employees XXXX. a Adaptive XXXX catalysts As year strong to
into like to address performance conference. go and the I we upcoming JPMorgan our details Before annual an initiative at communicated important milestones, I'd
Slide T-Detect Microsoft. T Adaptive these we medicine key our and business to As clonoSEQ on MRD immune of is support X efforts to clinicians medicine. mapping capital drug discovery, offered with and going The discuss areas. begin reporting immune to pharma cell will drug of development and our to This comprised aim ImmunoSEQ by on driven Genentech, business includes areas by X, business and effectively is Nykode, based forward, the approvals. around MRD growth, next test our quarter. research revenues distinct drive TMAP. diagnostics, the We clonoSEQ shown business and allocate to and and assay offered X franchise The partners diagnostic comprised
Turning to Slide X.
our XX% the can information MRD with CLL for our clonoSEQ mid-year. expanded You which and business, fourth of strong impact Despite trained revenue, fully we the Revenue in from grew the up additional patients, And team, be sales provides an the the assay version in field we mutation clonoSEQ of enhanced will diagnosis. time status which launched COVID by million year the the $XXX.X In The delivered significant see progress quarter we and year. ended we growth versus the throughout XX%. in variance, XXXX. made at
of demonstrating for clonoSEQ addition, clinical were studies clinical In utility patients. multiple published,
partnership milestones the from in in test our XXXX. trials continue year. of started pan-portfolio Regulatory to with pharma signed MRD during be $XX million clinical the accelerate recognized to major X in We having revenue agreements choice
immune business. our medicine We also achieved important milestones in
proof personalized TCR Genentech XX we as the in from the completed product, also Throughout made which progress selected patients. blood a year, TCRs identified program, using As about initial candidate mentioned, significant progress tumor-specific prioritized on on we concept product. to a cancer of and has shared successfully the therapeutic
capabilities cell our a the drug and of was used our extension half for and will into vaccines T of to I/II that Nykode with clinical our expect initiated first year. T data the of Nykode design achievement the be trial data cell-based development collaboration. key inform this has its the we Another discovery vaccine. first This time SARS-CoV-X Phase is in
inform treat Importantly, a of different cell-based to adaptive technology T design vaccines the diseases. of new class may
of the an by authorized We important also test COVID. T our progress and franchise, clearly T-Detect. the the milestone for great T-Detect marked authorization strategic is T-Detect This made in cell-based emergency by highlighted use first FDA
which validation Adaptive. by We also study Lyme ImmuneSense the first clinical conducted is the completed study successfully
We our hard consumer enable of season identified disorders, leverage COVID. learned in we Lyme to signals our In T-Detect expect lab pay Lyme this to demonstrating CLIA autoimmune and we applicability T-Detect during in to our that diseases. X class from the technology of experience offering diagnose
pharma T-MAP multiple This Lastly, by such response as J&J, for product across important T the which data and of being just COVID response I'd pharma used vaccines. product, like understand beginning is the COVID ability a AstraZeneca Moderna the our mapping touch to to our leverage is to traction as to immune diseases. partners of understand the on cell to
in during our MRD in a XXXX. trials. same partnerships growth achieved therapy of on going adoption of trials. of and and the in The pharma inclusion adoption significant is traction validation clonoSEQ clinicians its clones to development provide integration At drug and the trials clonoSEQ I'm X. synergy clinical awareness pharma decisions Now starting sensitivity. clinical for clinical to clinical pharma of an Slide strong practice more Both value of in and increases with business, There on drives make and between pharma clonoSEQ time, testing inclusion the the raises details MRD as endpoint
XX,XXX growth in XXXX the the ordering and significant XX%, XX% of tests tests. For experienced XX% grew all tests done were to Ordering and and care year, respectively, blood. health XX% full accounts delivered of providers versus approximately
the the holidays. few in experienced December, last the with intersection we of surge the weeks During of Omicron slowdown a
we will overcome to in uptake our seen XXXX. team and last our our community setting. such trajectory and commercial the year's January began headwinds investments, an accelerate us readouts anticipate the that reaching sales enable a with growth data However, that commercial We focus in we expansion of of have expanding offering
have goal team Our to by reach the out centers deepen the fully our academic and in community. built allow is to sales will into us and which increase our trained penetration midyear,
already indications, our growth multi clonoSEQ lymphoma. we myeloma offering. testing increase through CLIA our part It for and for seeking is note As are of NHL in large are B that expand diffuse to and coverage Medicare important to strategy blood-based cell available blood
side, used assay XX active XXX by being clonoSEQ currently pharma our pharma trials is the On companies. in than more
endpoint $XXX across Importantly, these revenue, we also regulatory than have across and indications all more drug clinical modalities. as Through milestones. a multiple use development we're in to embedded clinical with sample partnerships, access addition to million different phases the sequencing of per in
turn let's to Now business on medicine immune Slide X.
T-Detect, to progress X now with We infectious discovery identify our platform and have and receptors this and diseases for for their that steps. to antigens source disorders. building are T efforts. disease-specific shows the been strategy and code a in serve and map necessary We T-Detect, advanced success Slide indications other COVID organizing capabilities autoimmune repeat our as to next our teams drug the most validated in the efforts partnerships cell pharma
a consumers XX,XXX ordered During T-Detect COVID XXXX, test. over
pandemic of surges. the during increases part, For the followed most course significant orders the with variant
correlate to a will will T is provide in Crohn's as to the to recognize evolves. modest presented the data signal Conference and best awareness we Colitis This potential and the XXXX activities maintain for first proposition signal monitor with vaccine increase path cell the of of value endemic confirmed behaviors distinct to the as promotional week. to was pandemic T-Detect. updates the of offer and we're data We're T communication We continue with autoimmune the from FDA with specific continue Organisation's Crohn's at year those other European test measures in this Scientific progresses. efficacy. protection direct To to state, were space a working a the generate being generation We demonstrated determine consumers that colitis. to forward, ileal cells and demand and manufacturers in data the
of which identification and encouraging the colitis. supported in Crohn's signal also over samples, analysis X,XXX IBD We colonic completed
multiple to increases. understand important IBD, to a have and more confirmed classifiers sample that in It's addition In in identified size sensitive signal sclerosis our get the an we arthritis. TCR early rheumatoid signal as
partners. order meaningful focus a Our designing signals disorders high stages increasing the year false initiate of these large our our inform protocol positives. minimize by we're autoimmune autoimmune drug in we sensitivity a this opportunity that believe maintaining in is clinical significantly clinical market IBD. diagnostics To end, We while development with in validation that pharma represent opportunity specificity final to for to differentiated to and extremely improve
Slide Lastly, in therapy our cell shows progress X with collaboration Genentech.
good our both We shared progress private continue with make and to programs.
our we Regarding and safety neoantigen. delivered TCR data cancer candidate targets shared shared that a a program, for efficacy
to Genentech Following the using neoantigen-specific a TCR. TCR up to Adaptive selected track data Genentech candidate, proof-of-concept on data Francisco year, samples packages. we in cancer using process San following and screens. optimize successful private our This centralize, review generated recently we're both additional TCR lab. this initial of additional to and this program, personalized purpose-built aim the South this by Also, In Genentech our patient year, X test deliver
update. product establish the package. over Piskel private with early specifications closely development. personalized our data we build to this Kyle data work for to private The product generate financial Genentech pass continue year to product We now that our I'll Genentech define will with it and
